^
Association details:
| Biomarker: | YKL-40 overexpression |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | oxaliplatin (DNA synthesis inhibitor, DNA cross linking agent) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Upregulation of YKL-40 Promotes Metastatic Phenotype and Correlates with Poor Prognosis and Therapy Response in Patients with Colorectal Cancer
Published date:
11/11/2022
Excerpt:
Strikingly, high YKL-40 tissue levels showed a predictive value for a better response to cetuximab, even in patients with stage IV CRC and mutant KRAS...KRAS-mutant patients with YKL-40high showed a significantly longer PFS duration...Finally, we evaluated the role of the YKL-40 expression level in the response to oxaliplatin therapy. In this case, significantly shorter survival (OS) was associated with elevated YKL-40 gene expression.
DOI:
10.3390/cells11223568
